Home | Molecular Cancer Therapeutics

January 2020
Read the January 2020 issue!
A Multi-functional Therapy Approach for Cancer: Targeting Raf1- mediated Inhibition of Cell Motility, Growth and Interaction with the Microenvironment
Limin Zhang, et al.
Precision Chemo-Radiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell Permeability
Dina V. Hingorani, et al.
Review: The Ongoing Search for Biomarkers of CDK4/6 Inhibitor Responsiveness in Breast Cancer
Scott F. Schoninger and Stacy W. Blain

From the Current Issue

Review

The Ongoing Search for Biomarkers of CDK4/6 Inhibitor Responsiveness in Breast Cancer

Scott F. Schoninger and Stacy W. Blain

Mol Cancer Ther January 1 2020 19 (1) 3-12; DOI:10.1158/1535-7163.MCT-19-0253
Small Molecule Therapeutics | AuthorChoice

Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically

Lucy C. Riches, Antonio G. Trinidad, Gareth Hughes, Gemma N. Jones, Adina M. Hughes, Andrew G. Thomason, Paul Gavine, Andy Cui, Stephanie Ling, Jonathan Stott, Roger Clark, Samantha Peel, Pendeep Gill, Louise M. Goodwin, Aaron Smith, Kurt G. Pike, Bernard Barlaam, Martin Pass, Mark J. O'Connor, Graeme Smith and Elaine B. Cadogan

Mol Cancer Ther January 1 2020 19 (1) 13-25; DOI:10.1158/1535-7163.MCT-18-1394
Large Molecule Therapeutics | AuthorChoice

Precision Chemoradiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell Permeability

Dina V. Hingorani, Matthew K. Doan, Maria F. Camargo, Joseph Aguilera, Seung M. Song, Donald Pizzo, Daniel J. Scanderbeg, Ezra E.W. Cohen, Andrew M. Lowy, Stephen R. Adams and Sunil J. Advani

Mol Cancer Ther January 1 2020 19 (1) 157-167; DOI:10.1158/1535-7163.MCT-18-1302
Cancer Biology and Translational Studies

ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2^−/− Ovarian Cancer Cells

Lu Liu, Shurui Cai, Chunhua Han, Ananya Banerjee, Dayong Wu, Tiantian Cui, Guozhen Xie, Junran Zhang, Xiaoli Zhang, Eric McLaughlin, Ming Yin, Floor J. Backes, Arnab Chakravarti, Yanfang Zheng and Qi-En Wang

Mol Cancer Ther January 1 2020 19 (1) 199-210; DOI:10.1158/1535-7163.MCT-19-0242
Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers

ADP-Ribosylation Levels and Patterns Correlate with Gene Expression and Clinical Outcomes in Ovarian Cancers

Lesley B. Conrad, Ken Y. Lin, Tulip Nandu, Bryan A. Gibson, Jayanthi S. Lea and W. Lee Kraus

Mol Cancer Ther January 1 2020 19 (1) 282-291; DOI:10.1158/1535-7163.MCT-19-0569

See the Table of Contents

Recent Reviews

Review | AuthorChoice

Cabozantinib in Combination with Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence

Paulo Bergerot, Peter Lamb, Evelyn Wang and Sumanta K. Pal

Mol Cancer Ther December 1 2019 18 (12) 2185-2193; DOI:10.1158/1535-7163.MCT-18-1399
Reviews | AuthorChoice

ATM Dysfunction in Pancreatic Adenocarcinoma and Associated Therapeutic Implications

Samantha A. Armstrong, Christopher W. Schultz, Ariana Azimi-Sadjadi, Jonathan R. Brody and Michael J. Pishvaian

Mol Cancer Ther November 1 2019 18 (11) 1899-1908; DOI:10.1158/1535-7163.MCT-19-0208
Reviews

Targeting the EGFR and Immune Pathways in Squamous Cell Carcinoma of the Head and Neck (SCCHN): Forging a New Alliance

Nabil F. Saba, Zhuo Gerogia Chen, Missak Haigentz, Paolo Bossi, Alessandra Rinaldo, Juan P. Rodrigo, Antti A. Mäkitie, Robert P. Takes, Primoz Strojan, Jan B. Vermorken and Alfio Ferlito

Mol Cancer Ther November 1 2019 18 (11) 1909-1915; DOI:10.1158/1535-7163.MCT-19-0214

Main menu

User menu

Search

From the Current Issue

Recent Reviews

OnlineFirst Articles

Articles

Info for

About MCT